Not an Antidepressant but a Medicine for PE

Priligy (Dapoxetine Hydrochloride) is the first oral medication to be approved for the treatment of premature ejaculation (PE). Like Prozac and other antidepressants such as Paxil and Zoloft, Dapoxetine is a short acting selective serotonin reuptake inhibitor (SSRI). But Dapoxetine didn‘t pan out as an antidepressant, and the same thing that caused its failure as a psychopharmaceutical turned out to be the reason for its success as a treatment for premature ejaculation.
The rights and patents for the drug have changed hands a few times, and several pharmaceutical companies have their fingers in the Dapoxetine pie. The drug was originated by Eli Lilly, but in 1998, PPD GenuPro acquired the rights and from Eli Lilly to develop the drug as a premature ejaculation treatment. In 2001, PPD sold exclusive worldwide marketing and development rights for Dapoxetine to ALZA Corporation, which is an affiliate of Johnson & Johnson. In 2008, Dapoxetine was approved for marketing in Europe. And it was approved by CFDA for marketing in China in 2019.
We can supply impurity reference substances and impurity standards for Dapoxetine. More information is available on the official website: https://www.ex-biotech.com/. If you have any questions, please send an email to ramyan@ex-biotech.com, we look forward to cooperating with you.